Jan 7 Pharmacyclics Inc said its cancer
drug, Imbruvica, met its main goal of increasing patients'
survival without their cancer worsening in a late-stage trial.
The company's stock rose 5 percent at $110.60 on Tuesday on
the Nasdaq after the company said an independent safety
committee recommended an early halt of the trial.
The drug was being tested in patients with chronic
lymphocytic leukemia, a rare form of blood cancer that primarily
affects people aged 65 and older.
Pharmacyclics said it informed the U.S. Food and Drug
Administration of the committee's recommendations, while its
partner, Johnson & Johnson unit Janssen had informed the
(Reporting By Vrinda Manocha in Bangalore; Editing by Savio